|
1
|
Berx G and van Roy F: Involvement of
members of the cadherin superfamily in cancer. Cold Spring Harb
Perspect Biol. 1:a0031292009. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Davidson B, Berner A, Nesland JM, et al:
E-cadherin and alpha-, beta-, and gamma-catenin protein expression
is up-regulated in ovarian carcinoma cells in serous effusions. J
Pathol. 192:460–469. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Sundfeldt K, Piontkewitz Y, Ivarsson K, et
al: E-cadherin expression in human epithelial ovarian cancer and
normal ovary. Int J Cancer. 74:275–280. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Hazan RB, Kang L, Whooley BP and Borgen
PI: N-cadherin promotes adhesion between invasive breast cancer
cells and the stroma. Cell Adhes Commun. 4:399–411. 1997.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Qian X, Anzovino A, Kim S, et al:
N-cadherin/FGFR promotes metastasis through
epithelial-to-mesenchymal transition and stem/progenitor cell-like
properties. Oncogene. 33:3411–3421. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Van Roy F: Beyond E-cadherin: Roles of
other cadherin superfamily members in cancer. Nat Rev Cancer.
14:121–134. 2014. View
Article : Google Scholar : PubMed/NCBI
|
|
7
|
Chu K, Cheng CJ, Ye X, Lee YC, Zurita AJ,
Chen DT, Yu-Lee LY, Zhang S, Yeh ET, Hu MC, et al: Cadherin-11
promotes the metastasis of prostate cancer cells to bone. Mol
Cancer Res. 6:1259–1267. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Huang CF, Lira C, Chu K, et al:
Cadherin-11 increases migration and invasion of prostate cancer
cells and enhances their interaction with osteoblasts. Cancer Res.
70:4580–4589. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Nieman MT, Prudoff RS, Johnson KR and
Wheelock MJ: N-cadherin promotes motility in human breast cancer
cells regardless of their E-cadherin expression. J Cell Biol.
147:631–644. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Pishvaian MJ, Feltes CM, Thompson P, et
al: Cadherin-11 is expressed in invasive breast cancer cell lines.
Cancer Res. 59:947–952. 1999.PubMed/NCBI
|
|
11
|
Bignotti E, Tassi RA, Calza S, et al: Gene
expression profile of ovarian serous papillary carcinomas:
identification of metastasis-associated genes. Am J Obstet Gynecol.
196:245.e1–11. 2007. View Article : Google Scholar
|
|
12
|
Oliveira-Ferrer L, Rößler K, Haustein V,
et al: c-FOS suppresses ovarian cancer progression by changing
adhesion. Br J Cancer. 110:753–763. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Mahner S, Baasch C, Schwarz J, et al:
C-Fos expression is a molecular predictor of progression and
survival in epithelial ovarian carcinoma. Br J Cancer.
99:1269–1275. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Schröder C, Schumacher U, Müller V, et al:
The transcription factor Fra-2 promotes mammary tumour progression
by changing the adhesive properties of breast cancer cells. Eur J
Cancer. 46:1650–1660. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Hinz B, Pittet P, Smith-Clerc J,
Chaponnier C and Meister JJ: Myofibroblast development is
characterized by specific cell-cell adherens junctions. Mol Biol
Cell. 15:4310–4320. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Monahan TS, Andersen ND, Panossian H, et
al: A novel function for cadherin 11/osteoblast-cadherin in
vascular smooth muscle cells: Modulation of cell migration and
proliferation. J Vasc Surg. 45:581–589. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Orlandini M and Oliviero S: In fibroblasts
Vegf-D expression is induced by cell-cell contact mediated by
cadherin-11. J Biol Chem. 276:6576–6581. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Arnold KM, Opdenaker LM, Flynn D and
Sims-Mourtada J: Wound healing and cancer stem cells: Inflammation
as a driver of treatment resistance in breast cancer. Cancer Growth
Metastasis. 8:1–13. 2015.PubMed/NCBI
|
|
19
|
Dvorak HF: Tumors: Wounds that do not
heal. Similarities between tumor stroma generation and wound
healing. N Engl J Med. 315:1650–1659. 1986. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Delic S, Lottmann N, Jetschke K,
Reifenberger G and Riemenschneider MJ: Identification and
functional validation of CDH11, PCSK6 and SH3GL3 as novel glioma
invasion-associated candidate genes. Neuropathol Appl Neurobiol.
38:201–212. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Marchong MN, Yurkowski C, Ma C, Spencer C,
Pajovic S and Gallie BL: Cdh11 acts as a tumor suppressor in a
murine retinoblastoma model by facilitating tumor cell death. PLoS
Genet. 6:e10009232010. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
De Sousa E, Melo F, Wang X, Jansen M, et
al: Poor-prognosis colon cancer is defined by a molecularly
distinct subtype and develops from serrated precursor lesions. Nat
Med. 19:614–618. 2013. View
Article : Google Scholar : PubMed/NCBI
|
|
23
|
Deng Z, Niu G, Cai L, Wei R and Zhao X:
The prognostic significance of CD44V6, CDH11, and β-catenin
expression in patients with osteosarcoma. BioMed Res Int.
2013:4961932013. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Nakajima G, Patino-Garcia A, Bruheim S, et
al: CDH11 expression is associated with survival in patients with
osteosarcoma. Cancer Genomics Proteomics. 5:37–42. 2008.PubMed/NCBI
|
